

Title (en)
ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS

Title (de)
ALPHA-1a-ADRENORECEPTOR ANTAGONISTEN

Title (fr)
ANTAGONISTES DES ADRENORECEPTEURS ALPHA 1a

Publication
EP 1014973 A4 20000920 (EN)

Application
EP 98931320 A 19980617

Priority
• GB 9800219 A 19980107
• US 9812573 W 19980617
• US 5013697 P 19970618

Abstract (en)
[origin: WO9857632A1] This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

IPC 1-7
C07D 263/26; C07D 239/34; A61K 31/415; A61K 31/42; A61K 31/425; A61K 31/505; A61K 31/275; C07D 491/08; C07D 487/04; C07D 233/02; C07D 275/06

IPC 8 full level
C07D 233/74 (2006.01); **A61K 31/277** (2006.01); **A61K 31/40** (2006.01); **A61K 31/4166** (2006.01); **A61K 31/421** (2006.01); **A61K 31/426** (2006.01); **A61K 31/428** (2006.01); **A61K 31/4439** (2006.01); **A61K 31/513** (2006.01); **A61P 13/08** (2006.01); **A61P 43/00** (2006.01); **C07C 255/46** (2006.01); **C07C 271/24** (2006.01); **C07D 207/24** (2006.01); **C07D 207/263** (2006.01); **C07D 207/36** (2006.01); **C07D 207/404** (2006.01); **C07D 263/20** (2006.01); **C07D 263/26** (2006.01); **C07D 275/06** (2006.01); **C07D 277/14** (2006.01); **C07D 413/12** (2006.01); **C07D 417/12** (2006.01); **C07D 487/04** (2006.01); **C07D 491/048** (2006.01)

CPC (source: EP)
A61P 13/08 (2017.12); **A61P 43/00** (2017.12); **C07C 255/46** (2013.01); **C07D 263/26** (2013.01); **C07D 275/06** (2013.01); **C07C 2601/02** (2017.04); **C07C 2601/14** (2017.04); **C07C 2603/18** (2017.04)

Citation (search report)
• [X] WO 9717969 A1 19970522 - SYNAPTIC PHARMA CORP [US], et al
• [Y] WO 9718209 A1 19970522 - MERCK & CO INC [US], et al
• [Y] US 5620993 A 19970415 - PATANE MICHAEL A [US], et al
• See references of WO 9857632A1

Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

DOCDB simple family (publication)
WO 9857632 A1 19981223; AU 8147498 A 19990104; CA 2294591 A1 19981223; EP 1014973 A1 20000705; EP 1014973 A4 20000920; JP 2002511086 A 20020409

DOCDB simple family (application)
US 9812573 W 19980617; AU 8147498 A 19980617; CA 2294591 A 19980617; EP 98931320 A 19980617; JP 50472099 A 19980617